





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address, COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC. 20201 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/766,154	01/19/2001	Clive Patience	61750-311	1279
75	03/27/2002			
Allen J. Grant, Esq., c/o Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein 6 Becker Farm Road			EXAMINER	
			BECKERLEG, ANNE M	
Roseland, NJ 07068			ART UNIT	PAPER NUMBER
			1632	
			DATE MAILED: 03/27/2002	Þ

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		09/766,154	PATIENCE, CLIVE		
		Examiner	Art Unit		
		Anne M Beckerleg	1632		
	The MAILING DATE of this communication app	_	1		
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status 1)□	Passansive to communication(s) filed on				
2a)☐	Responsive to communication(s) filed on This action is FINAL . 2b) Thi	· s action is non-final.			
	,—		attore, procedution as to the morite is		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-44</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
	Claim(s) is/are rejected.				
	Claim(s) is/are objected to.				
•	Claim(s) <u>1-44</u> are subject to restriction and/or e	election requirement.			
	•				
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	v Summary (PTO-413) Paper No(s) f Informal Patent Application (PTO-152)		

Application/Control Number: 09/766,154 Page 2

Art Unit: 1632

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13, drawn to processes for treating or preventing disease using tissue from a swine free of PERV, classified in class 424, subclass 93.2.
- II. Claims 14-25, drawn to methods of screening animals form an ERV, classified in class 435, subclass 373.
- III. Claims 26-44, drawn to an inbred miniature swine free of PERV and methods of producing an ERV-free animal, classified in class 800, subclass 8.

The inventions are distinct, each from the other because of the following reasons:

1) Inventions I and II are patentably distinct in that the methods of invention I are *in vivo* methods of administering cells or tissue, whereas the methods of invention II are *in vitro* methods of screening blood. As such the two methods utilize different reagents, operate under substantially different conditions, and have different modes of operation, different functions, and different effects.

2)Inventions II and III are patentably distinct in that the methods of invention III are *in vivo* methods of selective animal breeding, whereas the methods of invention II are *in vitro* methods of screening blood. As such the two methods utilize different reagents, operate under substantially different conditions, and have different modes of operation, different functions, and different effects.

Application/Control Number: 09/766,154 Page 3

Art Unit: 1632

3) Inventions I and III are related in part as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the methods of invention I can be practiced with regular swine that are not miniature and are not DD haplotype, AND the miniature swine of invention III can be used in the process of making ERV free non-human mammals. Further, the methods of treating disease using tissue or cells of invention I have substantially different modes of operation, different functions, and different effects than the breeding methods of invention III.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, different classification, and different search requirements, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Beckerleg, Ph.D., whose telephone number is (703) 306-9156. The examiner can be

Application/Control Number: 09/766,154

Art Unit: 1632

reached Mon-Thurs and every other Friday from 9:30-7:00. If the examiner is not available, the examiner's supervisor, Deborah Reynolds, can be reached at (703) 305-4051. General inquiries should be directed to the group receptionist whose phone number is (703) 308-0196. The technology center fax number is (703) 308-4242, the examiner's direct fax number is (703) 746-7024.

Dr. A.M.S. Beckerleg

A.M.S. BECKERLEG. PATENT EXAMINER

Page 4